BCDA MEXC RealStocks
Own real BCDA shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1
Last updated: 2026-11-19 05:25:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
BioCardia, Inc. (BCDA) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $0.78, with a market capitalization of $11.96M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.66 to $1.80. This page covers its latest market performance, valuation, price trends and company information.
$11.96M | |
$0.85 | |
$0.85 | |
$0.76 | |
$0.79 | |
22.56K | |
205.80K | |
-- | |
$1.80 | |
$0.66 | |
-- | |
2026-06-30 |
BioCardia, Inc. (BCDA) last closed at $0.78 as of 2026-11-18 23:50:00, down 2.68% ($0.02) from the previous close of $0.79.
During the latest regular trading session, BCDA traded between $0.76 and $0.85, with a volume of 22.56K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, BioCardia, Inc. (BCDA) moved from $0.90 to $0.78, representing a decline of 14.03% ($0.13).
The stock traded between $0.66 and $0.98 during the period. The latest price is near the middle of the 7-day range, indicating strong downward.
The average daily volume was 98.94 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 10.1%
BCDA is currently trading at $0.78, placing it 10.1% of the way from its 52-week low of $0.66 to its 52-week high of $1.80. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 21 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of BioCardia, Inc. (BCDA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to BCDA, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between BCDA shares and USD.
BCDA Shares to USD
1.00 BCDA shares = 0.776 USD
Calculations are estimates based on the latest available price and are for reference only.